Malaria - Pipeline Review, H2 2017

Date: November 14, 2017
Pages: 372
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ME58845C40CEN
Leaflet:

Download PDF Leaflet

Malaria - Pipeline Review, H2 2017
Malaria - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malaria - Pipeline Review, H2 2017, provides an overview of the Malaria (Infectious Disease) pipeline landscape.

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malaria - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 13, 13, 57 and 29 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 12, 46 and 42 molecules, respectively.

Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Malaria - Overview
Malaria - Therapeutics Development
Malaria - Therapeutics Assessment
Malaria - Companies Involved in Therapeutics Development
Malaria - Drug Profiles
Malaria - Dormant Projects
Malaria - Discontinued Products
Malaria - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Malaria, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Malaria - Pipeline by 4SC AG, H2 2017
Malaria - Pipeline by AbbVie Inc, H2 2017
Malaria - Pipeline by Actelion Pharmaceuticals Ltd, H2 2017
Malaria - Pipeline by Agilvax Inc, H2 2017
Malaria - Pipeline by Akshaya Bio Inc, H2 2017
Malaria - Pipeline by Allergy Therapeutics Plc, H2 2017
Malaria - Pipeline by Altimmune Inc, H2 2017
Malaria - Pipeline by Amura Holdings Ltd, H2 2017
Malaria - Pipeline by Artificial Cell Technologies Inc, H2 2017
Malaria - Pipeline by AstraZeneca Plc, H2 2017
Malaria - Pipeline by Bharat Biotech International Ltd, H2 2017
Malaria - Pipeline by Cadila Healthcare Ltd, H2 2017
Malaria - Pipeline by Carna Biosciences Inc, H2 2017
Malaria - Pipeline by CEL-SCI Corp, H2 2017
Malaria - Pipeline by Celgene Corp, H2 2017
Malaria - Pipeline by Cilian AG, H2 2017
Malaria - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Malaria - Pipeline by DesignMedix Inc, H2 2017
Malaria - Pipeline by Eisai Co Ltd, H2 2017
Malaria - Pipeline by Expres2ion Biotechnologies ApS, H2 2017
Malaria - Pipeline by Fosun International Ltd, H2 2017
Malaria - Pipeline by GenVec Inc, H2 2017
Malaria - Pipeline by Genzyme Corp, H2 2017
Malaria - Pipeline by GeoVax Labs Inc, H2 2017
Malaria - Pipeline by GlaxoSmithKline Plc, H2 2017
Malaria - Pipeline by Hager Biosciences LLC, H2 2017
Malaria - Pipeline by iBio Inc, H2 2017
Malaria - Pipeline by Ichor Medical Systems Inc, H2 2017
Malaria - Pipeline by Immunovaccine Inc, H2 2017
Malaria - Pipeline by IPCA Laboratories Ltd, H2 2017
Malaria - Pipeline by Jomaa Pharma GmbH, H2 2017
Malaria - Pipeline by Kancera AB, H2 2017
Malaria - Pipeline by Kymab Ltd, H2 2017
Malaria - Pipeline by Lipocure Ltd, H2 2017
Malaria - Pipeline by Lipotek Pty Ltd, H2 2017
Malaria - Pipeline by LondonPharma Ltd, H2 2017
Malaria - Pipeline by Marinomed Biotechnologie GmbH, H2 2017
Malaria - Pipeline by Merck KGaA, H2 2017
Malaria - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2017
Malaria - Pipeline by Microbiotix Inc, H2 2017
Malaria - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Malaria - Pipeline by Mucosis BV (Inactive), H2 2017
Malaria - Pipeline by Mymetics Corp, H2 2017
Malaria - Pipeline by Nobelpharma Co Ltd, H2 2017
Malaria - Pipeline by Novartis AG, H2 2017
Malaria - Pipeline by Osivax SAS, H2 2017
Malaria - Pipeline by Otsuka Holdings Co Ltd, H2 2017
Malaria - Pipeline by PaxVax Inc, H2 2017
Malaria - Pipeline by Pfizer Inc, H2 2017
Malaria - Pipeline by Protein Potential LLC, H2 2017
Malaria - Pipeline by Rodos BioTarget GmbH, H2 2017
Malaria - Pipeline by Sanaria Inc, H2 2017
Malaria - Pipeline by Sanofi, H2 2017
Malaria - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017
Malaria - Pipeline by Selecta Biosciences Inc, H2 2017
Malaria - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Malaria - Pipeline by Theravectys SA, H2 2017
Malaria - Pipeline by Titan Pharmaceuticals Inc, H2 2017
Malaria - Pipeline by Toyama Chemical Co Ltd, H2 2017
Malaria - Pipeline by VLP Biotech Inc, H2 2017
Malaria - Pipeline by VLP Therapeutics LLC, H2 2017
Malaria - Dormant Projects, H2 2017
Malaria - Dormant Projects, H2 2017 (Contd..1), H2 2017
Malaria - Dormant Projects, H2 2017 (Contd..2), H2 2017
Malaria - Dormant Projects, H2 2017 (Contd..3), H2 2017
Malaria - Dormant Projects, H2 2017 (Contd..4), H2 2017
Malaria - Dormant Projects, H2 2017 (Contd..5), H2 2017
Malaria - Dormant Projects, H2 2017 (Contd..6), H2 2017
Malaria - Dormant Projects, H2 2017 (Contd..7), H2 2017
Malaria - Discontinued Products, H2 2017
Malaria - Discontinued Products, H2 2017 (Contd..1), H2 2017

LIST OF FIGURES

Number of Products under Development for Malaria, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

4SC AG
AbbVie Inc
Actelion Pharmaceuticals Ltd
Agilvax Inc
Akshaya Bio Inc
Allergy Therapeutics Plc
Altimmune Inc
Amura Holdings Ltd
Artificial Cell Technologies Inc
AstraZeneca Plc
Bharat Biotech International Ltd
Cadila Healthcare Ltd
Carna Biosciences Inc
CEL-SCI Corp
Celgene Corp
Cilian AG
Daiichi Sankyo Co Ltd
DesignMedix Inc
Eisai Co Ltd
Expres2ion Biotechnologies ApS
Fosun International Ltd
GenVec Inc
Genzyme Corp
GeoVax Labs Inc
GlaxoSmithKline Plc
Hager Biosciences LLC
iBio Inc
Ichor Medical Systems Inc
Immunovaccine Inc
IPCA Laboratories Ltd
Jomaa Pharma GmbH
Kancera AB
Kymab Ltd
Lipocure Ltd
Lipotek Pty Ltd
LondonPharma Ltd
Marinomed Biotechnologie GmbH
Merck KGaA
MerLion Pharmaceuticals Pte Ltd
Microbiotix Inc
Mitsubishi Tanabe Pharma Corp
Mucosis BV (Inactive)
Mymetics Corp
Nobelpharma Co Ltd
Novartis AG
Osivax SAS
Otsuka Holdings Co Ltd
PaxVax Inc
Pfizer Inc
Protein Potential LLC
Rodos BioTarget GmbH
Sanaria Inc
Sanofi
SBI Pharmaceuticals Co Ltd
Selecta Biosciences Inc
Takeda Pharmaceutical Co Ltd
Theravectys SA
Titan Pharmaceuticals Inc
Toyama Chemical Co Ltd
VLP Biotech Inc
VLP Therapeutics LLC
Skip to top


Malaria - Pipeline Review, H1 2017 US$ 2,000.00 May, 2017 · 365 pages
Seek - Product Pipeline Review - 2014 US$ 1,500.00 Oct, 2014 · 42 pages
Amura Holdings Ltd. - Product Pipeline Review - 2015 US$ 1,500.00 Apr, 2015 · 22 pages
DesignMedix, Inc. - Product Pipeline Review - 2015 US$ 1,500.00 Dec, 2015 · 20 pages
Mucosis B.V. - Product Pipeline Review - 2015 US$ 1,500.00 Jul, 2015 · 27 pages

Ask Your Question

Malaria - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: